U.S. Biotech Stock News

Stock performance snapshot and context SM Energy (SM) has drawn investor attention after a period of weak share performance, with the stock showing a 56.1% negative total return over the past year and a 41.2% negative total return over three years. See our latest analysis for SM Energy. At a recent share price of $18.21, SM Energy has seen pressure on its short term share price performance, with a 30 day share price return of a 6.18% decline and a 90 day share price return of a 14.35%...

American States Water (AWR) is back in focus after its Golden State Water subsidiary received approval for a $32 million rate increase from the California Public Utilities Commission, effective January 1, 2026. See our latest analysis for American States Water. The approved 2026 rate increase comes as American States Water’s share price sits at $75.97, with a 7 day share price return of 3.78% and a year to date share price return of 5.13%. The 1 year total shareholder return of 4.09%...

ACADIA Pharmaceuticals (ACAD) recently outlined its long term sales outlook at the 44th Annual J.P. Morgan Healthcare Conference, linking projected net sales above US$1b by 2025 and about US$1.7b by 2028 to its neurology portfolio. See our latest analysis for ACADIA Pharmaceuticals. The recent J.P. Morgan update, together with upcoming events like the DAYBUE STIX launch and the Biotech Showcase presentation in San Francisco, comes after a 24.4% 90 day share price return and a 47.9% 1 year...

Event context and recent share performance Huntsman (HUN) has been drawing attention after a stretch of mixed share performance, with a gain of 18.15% over the past month and a 28.68% decline over the past 1 year. See our latest analysis for Huntsman. For Huntsman, the recent 44.89% 3 month share price return contrasts with a 28.68% 1 year total shareholder return decline. This suggests short term momentum has picked up while longer term returns remain under pressure. If Huntsman’s mixed...

Starbucks, now led by CEO Brian Niccol, has begun executing its “Back to Starbucks” and Green Apron initiatives, recently returning to positive comparable-store sales while also addressing a high-profile public relations incident and ongoing waste and sustainability concerns. At the same time, Starbucks is reshaping its global footprint by selling most of its China stake and preparing to report first-quarter fiscal 2026 results, developments that could influence how investors judge the early...

Why EVERTEC (EVTC) is on investors’ radar today EVERTEC (EVTC) has drawn investor attention after its latest financial metrics highlighted solid transaction processing activity across Latin America and the Caribbean, with annual revenue of US$903.381m and net income of US$146.091m. Those headline figures, combined with mixed recent share returns and an assigned value score of 5, are prompting investors to reassess how this regional payments and fintech provider fits into a diversified...

Regulatory catalyst and expanding oncology reach Zai Lab (ZLAB) has drawn fresh investor attention after China’s National Medical Products Administration approved a supplemental New Drug Application for AUGTYRO (repotrectinib) in NTRK fusion positive solid tumors, which broadens its potential treatment reach. See our latest analysis for Zai Lab. Despite the recent product approvals and pipeline updates, Zai Lab’s share price at US$18.58 reflects mixed momentum, with a 30 day share price...

Wondering if UMB Financial at around US$122 per share is offering fair value right now, or if the price is leaving some upside on the table for patient investors? The stock has recently shown steady returns, with about 0.4% over the last week, 2.6% over the last month, 4.8% year to date and 3.6% over the past year, adding to longer term returns of 51.2% over three years and 76.6% over five years. Recent coverage of UMB Financial has focused on how investors are reassessing bank stocks more...

Why Amgen (AMGN) Is On Investors’ Radar Today Amgen (AMGN) is back in focus after recent trading pushed its share price close to recent levels, inviting a closer look at how its current valuation lines up with recent performance. See our latest analysis for Amgen. At around US$330.41 per share, Amgen’s recent 90 day share price return of 10.58% contrasts with a more moderate year to date share price return of 0.85%. The 1 year total shareholder return of 25.38% indicates stronger gains when...

Urban Outfitters, Inc. reported that total net sales for the two months and eleven months ended December 31, 2025, rose 9% and 11% respectively compared with the same periods in 2024, reflecting strong holiday-season performance ahead of its ICR Conference 2026 appearance in Orlando. This recent sales momentum highlights how Urban Outfitters’ holiday execution and merchandising appeal may be reinforcing its efforts to grow engagement across brands and channels. We’ll now explore how this...

Earlier in January 2026, Skyward Specialty Insurance Group expanded its E&S Property offering to include Excess coverage, enhancing support for layered, technically complex, non-catastrophe property risks. This move, paired with the appointment of Christopher Zitzmann to lead Inland Marine and Transactional E&S, underscores a clear focus on deepening expertise in specialized, less crowded insurance niches. We’ll now examine how the new Excess E&S Property capacity could influence Skyward...

How Trip.com Group stock has been trading recently Trip.com Group (TCOM) has seen mixed share performance, with a 0.8% move over the past day, contrasted with weaker returns over the week, month and past 3 months as investors reassess travel exposure. See our latest analysis for Trip.com Group. At a share price of $61.77, Trip.com Group’s recent 7 day share price return of an 18.36% decline and year to date share price return of a 17.08% decline contrast with a 3 year total shareholder return...

If you are wondering whether AdaptHealth's share price lines up with its underlying worth, you are not alone. This article focuses squarely on what the current price might be implying about value. The stock last closed at US$10.61, with returns of 1.1% over 7 days, 1.2% over 30 days, 9.7% year to date and 0.9% over 1 year. These figures are set against much weaker 3 year and 5 year returns of 49.5% and 72.1% declines. Recent coverage has focused on AdaptHealth's position in the home...

If you are wondering whether Driven Brands Holdings is attractively priced at its current level, this article walks through the numbers so you can judge the value story for yourself. The share price closed at US$15.52 most recently, with returns of 1.1% over the last 30 days, 7.0% year to date, and a 2.4% decline over the past year, alongside deeper 3 year and 5 year declines of 43.3% and 47.9%. Recent moves in the stock have drawn attention back to how the company is positioned in auto...

Paylocity Holding (PCTY) is back on investor radars after BTIG’s Allan Verkhovski initiated coverage with a Buy rating, alongside broadly positive brokerage sentiment and references to the company’s fundamental strength and recent technical stabilization. See our latest analysis for Paylocity Holding. At a share price of $140.10, Paylocity has seen a 7 day share price return of 6.84% and a year to date share price return of 3.84% decline, while the 1 year total shareholder return of 28.88%...

Recent performance snapshot for Amer Sports Amer Sports (NYSE:AS) has caught investor attention after a mixed run, with the share price showing a small 1 day decline and a modest pullback over the past week and month. At the same time, the stock has delivered a positive total return over the past 3 months and past year, inviting closer scrutiny of how recent performance lines up with the company’s current fundamentals. See our latest analysis for Amer Sports. That recent 1 day and 7 day share...

If you have been wondering whether US Foods Holding is priced fairly or not, this article walks through what the current share price might imply about its value. The stock last closed at US$85.71, with returns of 13.4% over the past 7 days, 11.2% over 30 days, 14.8% year to date, 25.5% over 1 year, 133.9% over 3 years and 146.5% over 5 years, which may catch the eye of investors thinking about what is already priced in. Recent attention on US Foods Holding has focused on how the business is...

Itron (ITRI) is back in the headlines after announcing a multi year collaboration with Thessaloniki based EYATH S.A. to deploy Smart Water Solutions across the Greek utility's network. See our latest analysis for Itron. For context, Itron's share price is now at $100.04, with a 30 day share price return of 5.68% and a year to date share price return of 5.90%. The 1 year total shareholder return is a 5.05% decline and the 3 year total shareholder return is 76.13%, suggesting long term holders...

If you are wondering whether CrowdStrike Holdings is still worth the price on the screen today, the key question is how that price compares to a fair assessment of its value. The stock last closed at US$453.88, with a 7 day return of a 3.6% decline, a 30 day return of a 3.4% decline, and a 1 year return of 27.1%. It is roughly flat year to date at 0.1% and shows a very large 3 year return that is around 3x. Recent headlines around CrowdStrike continue to highlight its role in cybersecurity...

Why the new rate hike opposition matters for Consolidated Edison (ED) Officials representing about 9 million New Yorkers are urging regulators to reject Consolidated Edison (ED) rate hikes for 2026 to 2028. They argue that even reduced electricity and gas increases strain households and small businesses. See our latest analysis for Consolidated Edison. Consolidated Edison’s share price has moved to $103.81, with a 1-day share price return of 1.20% and a 7-day share price return of 4.64%,...

OneMain Holdings (OMF) moved into focus after JP Morgan cut its rating from Neutral to Underweight. The call was centered on rising credit card and auto delinquencies among non prime borrowers. See our latest analysis for OneMain Holdings. The downgrade came after a sharp 5.1% drop, and that negative reaction is now sitting alongside a 7 day share price return of 7.73% and a 30 day share price return of 3.77% at a last close of US$65.40. Even so, the 90 day share price return of 20.82% and 1...

If you have been wondering whether Ally Financial's current share price offers real value or just headline appeal, this breakdown is designed to give you a clear, practical view. The stock closed at US$43.61, with returns of 22.0% over 1 year and 54.5% over 3 years, while the last 7 days and year to date show declines of 4.6% and 4.7% respectively. Recent coverage around Ally Financial has focused on its position as a listed diversified financials company, as investors weigh its exposure to...

If you are looking at Microchip Technology and wondering whether the current share price lines up with its underlying worth, you are not alone. The stock last closed at US$74.70, with recent returns of 16.7% over 30 days, 14.9% year to date, and 32.9% over the past year, although the 7 day return was a 0.7% decline. Recent interest around Microchip Technology has focused on how a well known semiconductor name fits into investor portfolios that are increasingly sensitive to price and quality...

FDA Breakthrough Therapy Designation: Why It Matters for Investors The latest move around Revolution Medicines (RVMD) is the FDA granting Breakthrough Therapy Designation to its RAS(ON) G12D inhibitor zoldonrasib for certain previously treated advanced non small cell lung cancer patients. See our latest analysis for Revolution Medicines. The Breakthrough Therapy news arrives after a period of sharp share price swings, with Revolution Medicines now trading at $120.28 and posting a 30 day share...